Press release
Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference
Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies,
About this update from Illumina, Inc.
[{"type":"text","content":"Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally\n\n\nSAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will advance the company's mission of improving human health by unlocking the power of the genome. \n\n \n \n \n \n \n \n\n \n\"We are seeing incredible acceleration of genomics in healthcare, driving an outstanding 2021 for Illumina and strong momentum for 2022 and beyond,\" said Francis deSouza, CEO of Illumina. \"With growth opportunities spanning our existing and evolving markets in both clinical and research genomics, we are demonstrating through focused and continued innovation how unlocking the power of the genome improves human health. Across all our markets, we are providing tools that enable today's researchers and clinicians to usher in the future of personalized medicine for patients around the world.\"\nPreliminary Consolidated Financial Results and Guidance\nIllumina delivered a strong finish to 2021, with preliminary consolidated fourth quarter revenue of approximately $1.190 billion, up 25% year-over-year. This record revenue for the quarter reflected records across both instruments and consumables. \nIllumina also delivered preliminary fiscal year 2021 consolidated revenue of approximately $4.517 billion, up 39% year-over-year, reflecting record revenue across all regions and the highest number of shipments in company history. The company expects another strong year in 2022, with consolidated revenue guidance of $5.15 billion to $5.24 billion, or growth of 14% to 16% year-over-year, as sequencing awareness, demand, and adoption increase. \nIllumina provided additional financial disclosures and guidance today as part of its presentation at the J.P. Morgan Healthcare Conference. A copy of the presentation and a replay of the webcast are available through the Investor Info section of Illumina's website.\nMultiple New Partnership Announcements to Accelerat...